ENVB

+ Watchlist + Portfolio

Enveric Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.31
52-Week Range: $1.25 – $17.64
Market Cap: $6.22M
P/E (TTM): —
EPS (TTM): -12.18
Dividend Yield: —

Advanced Metrics

Price/Book: 0.35
PEG Ratio: —
Return on Equity: -170.04%
Return on Assets: -87.34%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.21
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-5.02M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-2.43M

ENVB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$8.03M	$7.25M	$2.84M	$2.78M
Selling, General & Admin	$11.61M	$10.70M	$6.45M	$5.79M
Operating Expenses	$19.96M	$18.30M	$9.63M	$8.77M
Operating Income	-$19.96M	-$18.30M	-$9.63M	-$8.77M
EBITDA	-$19.52M	-$17.89M	-$9.29M	-$8.57M
Pretax Income	-$19.96M	-$17.26M	-$9.57M	-$8.77M
Income Tax	-$1.49M	$28.91K	$8.93K	$0.00
Net Income	-$18.50M	-$17.31M	-$9.57M	-$8.77M
Diluted EPS	-195.00	-1455.48	-228.48	-36.24
Diluted Shares	96400	143937	502899	334719

ENVB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.72M	$2.29M	$2.24M	$4.68M
Receivables	$0.00	$224.61K	$0.00	—
Current Assets	$18.43M	$3.58M	$2.73M	$4.94M
Total Assets	$19.55M	$4.30M	$3.08M	$5.10M
Current Liabilities	$4.00M	$2.34M	$1.49M	$918.40K
Total Debt	$63.82K	$0.00	—	—
Total Liabilities	$4.00M	$2.34M	$1.49M	$918.40K
Retained Earnings	-$79.21M	-$96.50M	-$106.07M	-$114.85M
Shareholders' Equity	$14.67M	$1.96M	$1.59M	$4.18M
Working Capital	$14.44M	$1.24M	$1.24M	$4.02M

ENVB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.15M	-$14.09M	-$7.73M	-$8.14M
Capital Expenditure	-$584.16K	-$5.18K	—	—
Free Cash Flow	-$17.73M	-$14.10M	-$7.73M	-$8.14M
Depreciation & Amortisation	$435.20K	$408.03K	$337.49K	$200.86K
Stock-Based Compensation	$2.62M	$2.15M	$1.56M	$827.32K
Investing Cash Flow	-$584.16K	$11.67K	$0.00	—
Financing Cash Flow	$18.18M	-$1.34M	$7.67M	$10.58M
Share Repurchases	$0.00	-$1.05M	$0.00	—
Net Change in Cash	$449.25K	-$15.43M	-$52.30K	$2.44M

ENVB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$746.37K	$1.26M	$402.42K	$372.18K	$345.97K
Selling, General & Admin	$1.36M	$1.22M	$1.43M	$1.78M	$1.25M
Operating Expenses	$2.19M	$2.52M	$1.87M	$2.19M	$1.63M
Operating Income	-$2.19M	-$2.52M	-$1.87M	-$2.19M	-$1.63M
EBITDA	-$2.11M	-$2.48M	-$1.83M	-$2.15M	-$1.60M
Pretax Income	-$2.18M	-$2.52M	-$1.87M	-$2.19M	-$1.63M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$2.18M	-$2.52M	-$1.87M	-$2.19M	-$1.63M
Diluted EPS	-14.58	-0.97	-10.81	—	-1.08
Diluted Shares	149815	2.60M	313242	—	1.51M

ENVB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$4.29M	$2.85M	$3.76M	$4.68M	$4.91M
Current Assets	$4.83M	$3.31M	$4.17M	$4.94M	$5.38M
Total Assets	$5.10M	$3.55M	$4.36M	$5.10M	$5.52M
Current Liabilities	$1.18M	$1.36M	$905.88K	$918.40K	$460.68K
Total Liabilities	$1.18M	$1.36M	$905.88K	$918.40K	$460.68K
Retained Earnings	-$108.26M	-$110.78M	-$112.65M	-$114.85M	-$116.48M
Shareholders' Equity	$3.92M	$2.18M	$3.46M	$4.18M	$5.06M
Working Capital	$3.65M	$1.94M	$3.26M	$4.02M	$4.91M

ENVB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.39M	-$1.89M	-$2.07M	-$1.78M	-$2.26M
Free Cash Flow	-$2.39M	-$1.89M	-$2.07M	-$1.78M	-$2.26M
Depreciation & Amortisation	$81.02K	$39.98K	$40.37K	$39.48K	$37.24K
Stock-Based Compensation	$193.85K	$206.26K	$186.98K	$240.23K	$88.67K
Financing Cash Flow	$4.45M	$449.10K	$2.99M	$2.69M	$2.50M
Net Change in Cash	$2.06M	-$1.44M	$917.39K	$904.28K	$246.37K

Market Snapshot

About

Enveric Biosciences, Inc. is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for the treatment of mental health disorders. The company's research focuses on next-generation synthetic cannabinoid derivatives designed to avoid psychoactive effects while retaining therapeutic benefits. Enveric is advancing candidates for conditions including anxiety, depression, and other psychiatric disorders. The company utilizes computational drug design and preclinical testing to develop proprietary compounds with improved safety and efficacy profiles.